Along this line, the amount of CD4(+)PD-1(+) and CD8(+)PD-1(+) is higher in TNBC versus luminal type A breast cancer patients, showing that in TNBC patients, the PD-1/PD-L1 axis is a target for immune checkpoint inhibitors [39]. Here, CD4 is linked to breast carcinoma.